Research ArticleArticle
Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins
Laurent Salphati, Xiaoyan Chu, Liangfu Chen, Bhagwat Prasad, Shannon Dallas, Raymond Evers, Donna Mamaril-Fishman, Ethan G. Geier, Jonathan Kehler, Jeevan Kunta, Mario Mezler, Loic Laplanche, Jodie Pang, Anja Rode, Matthew G. Soars, Jashvant D. Unadkat, Robert A. B. van Waterschoot, Jocelyn Yabut, Alfred H. Schinkel and Nico Scheer
Drug Metabolism and Disposition August 2014, 42 (8) 1301-1313; DOI: https://doi.org/10.1124/dmd.114.057976
Laurent Salphati
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Xiaoyan Chu
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Liangfu Chen
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Bhagwat Prasad
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Shannon Dallas
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Raymond Evers
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Donna Mamaril-Fishman
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Ethan G. Geier
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Jonathan Kehler
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Jeevan Kunta
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Mario Mezler
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Loic Laplanche
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Jodie Pang
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Anja Rode
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Matthew G. Soars
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Jashvant D. Unadkat
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Robert A. B. van Waterschoot
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Jocelyn Yabut
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Alfred H. Schinkel
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Nico Scheer
DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
Article Information
vol. 42 no. 8 1301-1313
PubMed
Print ISSN
Online ISSN
History
- Received March 6, 2014
- Accepted May 22, 2014
- Published online July 7, 2014.
Article Versions
- Earlier version (May 22, 2014 - 06:57).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Laurent Salphati,
- Xiaoyan Chu,
- Liangfu Chen,
- Bhagwat Prasad,
- Shannon Dallas,
- Raymond Evers,
- Donna Mamaril-Fishman,
- Ethan G. Geier,
- Jonathan Kehler,
- Jeevan Kunta,
- Mario Mezler,
- Loic Laplanche,
- Jodie Pang,
- Anja Rode,
- Matthew G. Soars,
- Jashvant D. Unadkat,
- Robert A. B. van Waterschoot1,
- Jocelyn Yabut,
- Alfred H. Schinkel, and
- Nico Scheer
- DMPK and Bioanalytical Research, Abbvie Deutschland GmbH & Co. KG, Ludwigshafen, Germany (M.M., L.L., R.A.B.v.W.); Metabolism and Pharmacokinetics, Bristol-Myers Squibb, Wallingford, Connecticut (M.G.S.); Genentech, Inc., South San Francisco, California (L.S., E.G.G., J.P.); Drug Metabolism and Pharmacokinetics, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania (L.C., D.M.-F., J.Ke.); Janssen Research and Development, LLC, Spring House, Pennsylvania (S.D., J.Ku.); Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey (X.C., R.E., J.Y., R.E.); Department of Pharmaceutics, University of Washington, Seattle, Washington (B.P., J.D.U.); Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (A.H.S.); and TaconicArtemis, Koeln, Germany (A.R., N.S.)
- Address correspondence to:
Dr. Nico Scheer, TaconicArtemis, Neurather Ring 1, 51063 Koeln, Germany. E-mail: nico.scheer{at}taconicartemis.com
Statistics from Altmetric.com
Article usage
In this issue
Research ArticleArticle
OATP1B1 and -1B3 Humanized Mice
Laurent Salphati, Xiaoyan Chu, Liangfu Chen, Bhagwat Prasad, Shannon Dallas, Raymond Evers, Donna Mamaril-Fishman, Ethan G. Geier, Jonathan Kehler, Jeevan Kunta, Mario Mezler, Loic Laplanche, Jodie Pang, Anja Rode, Matthew G. Soars, Jashvant D. Unadkat, Robert A. B. van Waterschoot, Jocelyn Yabut, Alfred H. Schinkel and Nico Scheer
Drug Metabolism and Disposition August 1, 2014, 42 (8) 1301-1313; DOI: https://doi.org/10.1124/dmd.114.057976
Research ArticleArticle
OATP1B1 and -1B3 Humanized Mice
Laurent Salphati, Xiaoyan Chu, Liangfu Chen, Bhagwat Prasad, Shannon Dallas, Raymond Evers, Donna Mamaril-Fishman, Ethan G. Geier, Jonathan Kehler, Jeevan Kunta, Mario Mezler, Loic Laplanche, Jodie Pang, Anja Rode, Matthew G. Soars, Jashvant D. Unadkat, Robert A. B. van Waterschoot, Jocelyn Yabut, Alfred H. Schinkel and Nico Scheer
Drug Metabolism and Disposition August 1, 2014, 42 (8) 1301-1313; DOI: https://doi.org/10.1124/dmd.114.057976
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement